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Abstract
Purpose: Although the significance of Interleukin-18 (IL-18) has been studied inpathogenesis of different cancers including, ovarian, gastric, breast, lung carcinomaand melanoma, its role in thyroid cancer- the most common endocrine malignancyhas not yet been looked at extensively. Hence, this study intended to examine therole of IL-18 in thyroid tumorigenesis. Methods: Sixty seven patients with benignthyroid diseases and 106 thyroid cancer patients (including 83 papillary, 6follicular, 9 medullary and 8 anaplastic thyroid carcinoma patients) were enrolledin the study. To accomplish the aim, the circulating levels of IL-18 were estimatedby enzyme linked immunosorbent assay (ELISA) from all patients and comparedwith controls. Further, protein expression of IL-18 was determined from theprimary tumors of the patients using immunohistochemistry. Results: It wasobserved that the circulating levels of IL-18 were significantly higher in allpatients: benign thyroid diseases (p = 0.006), papillary (p < 0.001), follicular (p =0.023), medullary (p = 0.002) and anaplastic thyroid cancer (p < 0.001) than thecontrols. In addition to this, IL-18 could well discriminate papillary (AUC = 0.627, p=0.008) and anaplastic thyroid carcinoma patients (AUC = 0.777, p = 0.011) frompatients with benign thyroid diseases. However, the difference between tumoralprotein expression of IL-18 in patients with benign thyroid diseases and thyroidcarcinoma was not significant. The Kaplan - Meier survival analysis revealed thatneither the circulating nor the tumoral protein expression of IL-18 was thesignificant predictor of disease free survival (DFS) or overall survival (OS) inpapillary thyroid cancer patients. Conclusion: Though not a significantprognosticator, circulating IL-18 may be useful as a differentiating factor in thyroidtumorigenesis and the increase in serum IL-18 levels may be provoked in responseto the tumor. Thus, including IL-18 along with the current treatment practice mayhave a significant role in better management of the disease. However, furtherexploration of this interleukin is required in a larger series of patients with longerfollow up period.
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1. IntroductionInterleukin-18 (IL-18), first discovered as Interferon-γ(IFN-γ) inducing factor, is a pleiotropic,proinflammatory cytokine with dual effects on tumordevelopment and progression.1 On one hand, it caninduce Th1 immune response, which is generallyregarded as the immune reaction acting againstmalignant tumors and on the other hand, it can promoteTh2 immune responses that may inhibit recognition ofcancer cells by immune cells, thus increasing theadhesion molecules, inducing production of angiogenic
factors, and promoting a prometastatic micro-environment.2,3IL-18 is secreted by multiple cell types, including T andB cells, monocytes, macrophages, and some tumor cells.4It can be secreted as both mature as well as inactiveforms. IL-18 receptor (IL-18R) contains a ligand bindingα chain and a signal transducing domain β chain.5 Onbinding of IL-18 to IL-18Rα, the IL-18Rβ transduces itssignal to activate the mitogen-activated protein kinase(MAPK) pathway.1 IL-18 is also a costimulatory factorfor the induction of IL–12 - mediated interferon-γproduction by Th cells. In a potential direct negative
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feedback mechanism, IFN-γ induces the expression ofthe antagonistic IL-18 binding protein (IL-18bp), whichacts to inhibit IL-18 activity, and this in turn controlsIL-18 induced production of IFN-γ.2 Thus, the activity ofIL-18 is regulated by IL-18bp. On the other hand,downregulated IL-12 and IFN-γ would theoreticallyresult in similarly reduced IL-18bp expression. Absenceof this negative stimulus substantially explains thatincreased concentrations of IL-18 were correlated withadvanced stages and were also found to beindependently associated with shorter overall survival(OS) in various human cancers.6Various studies indicated the role of IL-18 inpathogenesis of different cancers like, ovarian, gastric,breast, lung carcinoma and melanoma.1, 7-12 However, itsrole in thyroid cancer - the most common endocrinemalignancy has not yet been explored extensively.Hence, this study specifically aimed to examine the roleof IL-18 in benign thyroid disease and thyroid cancerpatients and correlate the results withclinicopathological parameters and disease outcome.
2. Methods and Materials
2.1. PatientsPatients with benign thyroid diseases (N = 67), andthyroid cancer (N = 106), (papillary thyroid cancer(PTC): N = 83, follicular thyroid cancer (FTC): N = 6,medullary thyroid cancer (MTC): N = 9 and anaplasticthyroid cancer (ATC): N = 8) enrolled at our institute,were included in the study. All these patients werewithout any history of autoimmune disease, did notreceive any pre-treatment and none of them were takingany immunosuppressive or immunomodulant drugs.Sixty seven percent (45/67) patients with benignthyroid diseases, suspicious for having malignancy wereoperated at our institute. The thyroid cancer patients,(except 4/8 ATC patients who were unresectable)underwent surgery at the Department of SurgicalOncology of our institute. Only PTC patients which weresimilar as those cited in our previous articles,13, 14 wereconsidered for the correlation analysis. Theclinicopathological characteristics of these PTC patientsare depicted in Table 1.13, 14 While the patients withother three types of thyroid cancers were included forincidental studies only, as the number of patients werevery low for statistical analysis. The clinicians of theinstitute decided the treatment strategies. The primarytreatment offered to the patients was either surgery orsurgery followed by radioiodine ablation (RIA) therapyor surgery followed by RIA therapy and radiotherapyboth. Surgery was performed by the oncosurgeons,
while the RIA therapy and radiotherapy were institutedat the Nuclear Medicine department and Radiotherapydepartment, respectively. The clinical andhistopathological details of the patients were noted fromthe case files maintained at the Medical recorddepartment of the institute. The histologicalclassification of the tumors was in accordance with theWHO classification. The PTC patients were stagedaccording to the AJCC/UICC TNM staging system andwere accordingly grouped into younger (< 45 years) andelder (≥ 45 years) age groups. The patients werefollowed for a period of 4 years or until death withinthat period. For OS analysis, complete follow-up detailswere obtained in 92% (76/83) of PTC patients. Amongstthem, 9% (7/76) patients had persistent disease andhence were excluded from the disease free survival(DFS) analysis. Thus, for DFS analysis, 69/76 PTCpatients were included.
2.2. Sample collectionAll samples were collected with informed consent fromthe subjects and the study was approved by InstitutionalScientific and Ethical Committees. Pretherapeutic bloodsamples were collected from all patients as well as from67 controls to determine the circulating levels of IL-18.Serum was separated after centrifugation and waspreserved at -80˚C until analysis. ForImmunohistochemical localisation of IL-18 proteinexpression, paraffin embedded tissue blocks of all thepatients (who underwent surgery) were retrieved fromthe Histopathology department of the institute.
2.3. Circulating levels of IL-18 by Enzyme linked
Immunosorbent Assay (ELISA)The circulating levels of IL-18 were estimated from theserum samples of the subjects using commerciallyavailable ELISA kit from Krishgen Biosystems, as permanufacturer’s instructions. The absorbance was read at450 nm in Multiskan® Spectrum MicroplateSpectrophotometer (Thermo Labsystems), within 30minutes of stopping the reaction. A standard curve wasplot in Graphpad prism 5 software with concentration ofstandards on X-axis and absorbance on Y-axis. Theunknown concentrations were interpreted by thesoftware from the standard curve generated. Theconcentrations of the diluted samples were multipliedby the dilution factor to determine the actualconcentration. The circulating levels were expressed asmean ± standard error (M ± SE) and for survivalanalysis, the median value was used as cut-off to dividethe PTC patients into low (≤ median) and high (>median) level groups, respectively.
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Table 1: Clinicopathological characteristics of PTC patientsCharacteristics N (%) Characteristics N (%)Age Bilaterality<45 years≥45 years 41 (49)42 (51) UnilateralBilateral 61 (74)22 (26)Gender Haemorrhagic areaFemaleMale 56 (68)27 (32) AbsentPresent 72 (87)11 (13)Tumour size NecrosisT1 (N=16)+T2 (N=22)T3 (N=30)+T4 (N=15) 38 (46)45 (54) AbsentPresent 67 (81)16 (19)Nodal status CalcificationAbsentPresent 30 (36)53 (64) AbsentPresent 32 (39)51 (61)Metastasis Extrathyroidal extensionAbsentPresent 73 (88)10 (12) AbsentPresent 52 (63)31 (37)Stage FibrosisEarly [Stage I (N=37) + Stage II (N=12)]Advanced [Stage III (N=11)+ StageIV(N=23)] 49 (59)34 (41) AbsentPresent 61 (74)22 (26)Lymphatic permeation InflammationAbsentPresent 67 (81)16 (19) AbsentPresent 46 (55)37 (45)Vascular permeation DifferentiationAbsentPresent 74 (89)09 (11) WellModerate/ Poor 76 (92)07 (08)Capsular Invasion MultifocalityAbsentPresent 55 (66)28 (34) AbsentPresent 64 (77)19 (23)Encapsulation Residual DiseaseWell encapsulatedPartially/Not encapsulated 76 (92)07 (08) AbsentPresent 24 (29)59 (71)TreatmentSurgery 29 (35)Surgery + RIA and/RT 54 (65) Surgery + RIA 50 (60)Surgery + RIA +RT 04 (05)Disease StatusReccurrence/Distant Metastasis (N=69) Alive/Dead (N=76)Absent 62 (90) Alive 68 (89)Present 07 (10) Dead 08 (11)Recurrence 3 (4)Distant metastasis 4 (6)Bone 1 (1.5)Lung 2 (3.0)Bone + Lung 1 (1.5)
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Figure 1: ROC curves of serum IL-18 in patients with thyroid diseases vs controls
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Table 2: Significance of circulating levels of IL-8, IL-12, IL-18 and TNF-α in patients with benign thyroid diseases and thyroidcarcinoma as compared to controlsSubjects Circulating IL-18M ± SE (pg/ml) p valueControls (N=67) 188.56 ± 31.82Benign thyroid disease (N=67) 305.81 ± 27.11 0.006*Thyroid carcinoma ( N=106) 430.18 ± 27.49 <0.001*0.003@Papillary thyroid carcinoma (N=83) 402.17 ± 28.05 <0.001*0.016@Follicular thyroid carcinoma (N=6) 439.22 ± 54.01 0.023*0.153@Medullary thyroid carcinoma (N=9) 510.81 ± 144.99 0.002*0.026@Anaplastic thyroid carcinoma (N=8) 617.04 ± 137.22 <0.001*0.001@*Significance of circulating IL-18 in patients vs controls@ Significance of circulating IL-18 in patients with thyroid cancer vs benign thyroid diseases
Table 3: Correlation of circulating levels of IL-18 with clinicopathological parameters of PTC patientsParameter N IL-18Mean ± SE p valueLymphatic permeationAbsent 67 371.24 ± 29.12 0.020Present 16 534.87 ± 72.45Haemorrhagic areaAbsent 72 374.22 ± 24.51 0.008Present 11 589.68 ± 129.34
Table 4: Incidence of the cytokine expression in patients with benign thyroid disease and thyroid cancerIL-18 expression N (%) Median IRS SignificanceBenign thyroid disease(N=45) 44 (98)Cytoplasmic 44 (98) 6Nuclear 33 (73) 4PTC (N=83) 83 (100)Cytoplasmic 82 (99) 6 χ2=3.032, r=+0.154, p=0.083Nuclear 63 (76) 4 χ2=0.001, r=+0.003, P=0.973FTC (N=6) 6 (100)Cytoplasmic 6 (100) 5 χ2=0.213, r=+0.129, p=0.645Nuclear 4 (67) 2.5 χ2=0.000, r=+0.022, P=1.000MTC (N=9) 9 (100)Cytoplasmic 8 (89) 4 χ2=0.000, r=+0.018, p=1.000Nuclear 6 (67) 4 χ2=0.000, r=-0.017, p=1.000ATC (N=4) 4 (100)Cytoplasmic 4 (100) 4 χ2=0.047, r=+0.110, p=0.829Nuclear 2 (50) 1 χ2=0.000, r=+0.018, p=1.000
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Table 5: Univariate survival analysis (of circulating and tumoral protein expression of IL-18) for DFS and OS in PTC patients(N=69)Disease free survival (DFS) Overall survival (OS)Circulating IL-18 N Patients relapsedN (%) Circulating IL-18 N Patients diedN (%)Low 34 3 (9) Low 38 5 (13)High 35 4 (11) High 38 3 (8)Log rank=0.126, df=1, p=0.723 Log rank=0.589, df=1, p=0.443IL-18 expressionCytoplasmic CytoplasmicLow 37 3 (8) Low 41 5 (12)High 32 4 (12) High 35 3 (9)Log rank=0.402, df=1, p=0.526 Log rank=0.285, df=1, p=0.594Nuclear NuclearLow 37 5 (13) Low 41 5 (12)High 32 2 (6) High 35 3 (9)Log rank=1.020, df=1, p=0.313 Log rank=0.244, df=1, p=0.621
(a) (b)
Figure 2: ROC curves of serum IL-18 in patients with thyroid cancer vs benign thyroid diseases
(a) (b) (c)
Figure 3: Photomicrographs showing staining for IL-18. Cytoplasmic and nuclear staining for IL-18 in (a) benign goitre, (b)Follicular variant of papillary carcinoma and (c) Negative control for IL-18 in PTC
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2.4. Tumoral protein expression of IL-18 by
Immunohistochemistry (IHC)For detection of IL-18 protein expression from tumors,3-5 μm thick sections were cut from the formalin fixedparaffin embedded tissue blocks and mounted on 3 -Aminopropyltriethoxysilane (APES) coated glass slides,followed by immunohistochemical staining with HRPpolymerization technique performed using primaryrabbit polyclonal IL-18 antibody from SantacruzBiotechnology, Inc. (sc - 7954) at 1:50 dilution andMACH4 Universal HRP-Polymer Detection System fromBiocare Medicals, USA; as per manufacturer’s protocolrecommendations. For retrieval of antigen, the sectionswere heated in 10 mM sodium citrate buffer (pH, 6.0) for20 minutes in a pressure cooker prior to application ofthe primary antibody. Scoring of the stained sectionswas done by two individual observers independently ina blinded fashion using a semiquantitativeImmunoreactive Score (IRS) method of Remelle andStegner (1987), based on staining positivity and stainingintensity.15 Staining positivity was scored as 0 for nostained cells, 1 for staining in 1% to 10% of cells, 2 forstaining in 11% to 50% of cells, 3 for staining in 50% to80% of cells and 4 for staining in > 80% of cells. Thestaining intensity was scored as 0 for no staining, 1 forweak/faint staining, 2 for moderate staining and 3 forintense/dark staining. The IRS score was then obtainedas a product of staining positivity and staining intensityand therefore, theoretically the scores could range from0 to 12. For statistical evaluation, cytoplasmic andnuclear expressions were scored independently andtaken into account separately. The median IRS was usedas cut-off value to divide the patients into low (≤ medianIRS) and high (> median IRS) expression groups,respectively.
2.5. Statistical analysisThe data were analyzed statistically using the StatisticalPackage for Social Sciences (SPSS) software version 16(SPSS Inc, USA). Independent Samples T-test was used tocompare the means of circulating levels. Receiver’soperating characteristic (ROC) curves were constructedto determine the discriminating efficacy of thecirculating IL-18. Two- tailed χ2 test was used tocompare the tumoral protein expressions. In case of lessthan five patients in the cells of 2 x 2 tables, Yate’scontinuity correction value alongwith its two-tailedsignificance was taken into consideration. Correlationbetween two parameters was calculated usingSpearman’s correlation coefficient (r) method.Univariate survival analysis was evaluated usingKaplan-Meier method and Log rank test was used toanalyse difference in survival curves and to assess theprognostic significance of DFS and OS. p values ≤ 0.05were considered to be significant.
3. Results
3.1. Circulating levels of IL-18 in healthy
individuals, patients with benign thyroid diseases
and thyroid cancerThe circulating levels (Mean ± Standard Error, M ± SE) ofIL-18 in controls, in patients with benign thyroid diseasesand thyroid cancer are depicted in Table 2.The circulating levels IL-18 were significantly higher inall patients: benign thyroid diseases (p = 0.006), PTC (p <0.001), FTC (p = 0.023), MTC (p = 0.002) and ATC (p <0.001) than the controls [Table 2].The ROC curves were generated to reveal the efficacy ofsignificantly elevated IL-18 levels in order todifferentiate the controls and patients with differentthyroid diseases. The results demonstrated that serumIL-18 levels could significantly differentiate patientswith benign thyroid diseases (AUC = 0.698, p < 0.001),PTC (AUC = 0.775, p < 0.001), FTC (AUC = 0.846, p =0.005), MTC (AUC = 0.813, p = 0.002) as well as ATCpatients (AUC = 0.868, p = 0.001) from controls [Figure1a-1e].Moreover, it was observed that, the levels of IL-18 werefound to be predominantly higher in PTC (p = 0.016),MTC (p = 0.026) and ATC (p = 0.001) as compared tothose in patients with benign thyroid diseases [Table 2].Further, when ROC curves were generated to explorethe power of significantly elevated serum IL-18 level todifferentiate the benign and thyroid carcinoma patients,the results showed that IL-18 showed gooddiscriminating efficacy between patients with PTC andbenign thyroid diseases (AUC = 0.627, p = 0.008) [Figure2a]. In addition to this, IL-18 could well discriminateATC patients from patients with benign thyroid diseases(AUC = 0.777, p = 0.011) [Figure 2b].The correlation of serum cytokine levels with theclinicopathological parameters of PTC patients havebeen depicted in Table 3. Significantly higher serumIL-18 levels were observed in patients whose tumorshad presence of lymphatic permeation (p = 0.020) andhaemorrhagic area (p = 0.008) relative to the tumorsshowing absence of lymphatic permeation andhaemorrhagic area, respectively [Table 3] while, no suchsignificant correlation of serum IL-18 was observed withrest of the clinicopathological parameters.
3.2. Tumoral protein expression of IL-18 in
patients with benign thyroid diseases and thyroid
carcinomaCytoplasmic and/or nuclear staining pattern wasobserved for IL-18. For statistical evaluation,cytoplasmic and nuclear expressions were scoredindependently and taken into account separately. Theincidence of the cytokine expression in patients with
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benign thyroid diseases and thyroid carcinoma has beendepicted in Table 4. In PTC patients, the cytoplasmicIL-18 expression, was higher as compared to thatobserved in patients with benign thyroid diseases.However, the difference was not statistically significant(χ2= 3.032, r = + 0.154, p = 0.083). While the incidence ofcytoplasmic or nuclear IL-18 immunoreactivity was notsignificantly different in patients with FTC, MTC or ATCand benign thyroid disease, respectively [Table 4].Figure 3, shows the representative staining of IL-18protein expression.The statistical analysis revealed that neither cytoplasmicnor the nuclear IL-18 expression exhibited significantrelationship with any of the clinicopathologicalparameters in PTC patients indicating that the incidenceof IL-18 immunoreactivity was nearly similar in the PTCpatients when subgrouped according to theclinicopathological variables.
3.3. Survival analysisKaplan-Meier survival analysis was evaluated for DFSand OS in PTC patients. The median level of serum IL-18(314.23 pg/ml), was used as cut-off value to divide thePTC patients into low (≤ median) and high (> median)level groups, respectively. It was observed that neitherthe circulating nor the tumoral protein expression ofIL-18 was the significant predictor of DFS or OS in PTCpatients [Table 5].
4. DiscussionThe results of the present study perceptibly reveal thatthe serum IL-18 levels could significantly discriminatethe patients with benign thyroid diseases as well as thePTC, FTC, MTC and ATC patients from controls.Additionally, it was efficient enough to distinguish thePTC and ATC patients from those with benign thyroiddiseases. Further, in PTC patients, a significant positivecorrelation was obtained between circulating IL-18 andpresence of lymphatic permeation and haemorrhagicareas in the tumors. In similarity with this, significantlyhigher concentration of IL-18 in the circulation ofpatients with different malignancies.4, 7, 16-42 Moreover,Matveeva and Mosina,43 through their study haverecommended the use of serum IL-18 for diagnosis ofatrophic gastritis, peptic ulcer disease and gastriccancer. Further, serum IL-18 levels were found to besignificantly elevated in prostate cancer patients thanboth controls and benign prostate hyperplasia44 and ingastric cancer patients than in gastric ulcer patients.45However, recently Bao et al.46 have reported significantlower serum IL-18 levels in hepatocellular carcinomapatients compared to the control group. Additionally, itslevels were also reported to be higher in polycysticovarian syndrome47, 48 and its possible correlation withartherosclerosis49 and its role as a cardiovascularmarker50, 51 has also been documented.
Further, IL-18 immunoreactivity was observed in thecytoplasm and nucleus of the thyroid cells. Although notsignificant, a trend of increased cytoplasmic expressionof IL-18 was observed in PTC patients as compared topatients with benign diseases, while the incidence ofnuclear IL-18 immunoreactivity was almost similar inpatients with benign thyroid diseases and PTC.Moreover, the cytoplasmic or nuclear IL-18 expressiondid not differ significantly in FTC, MTC or ATC patientsand the benign disease patients. The IL-18 expressionalso did not correlate with any of the clinicopathologicalparameters in the PTC patients. In similarity withpresent observation, Ye et al.11 also found that IL-18 wasdistributed in both cytoplasmic and nuclearcompartments of the gastric tumor cells while; Orengo et
al.37 have reported only cytoplasmic staining of IL-18 inepithelial ovarian cancer cells. Further, theimmunohistochemical analysis in a study by Okamoto et
al.33 revealed that IL-18 was strongly expressed in lungcancer cells and in bone metastasis. Srabovic et al.52have reported that IL-18 expression was significantlyhigher in breast cancer tumors relative to its expressionin surrounding unchanged tissue of the same patient butit was not higher than that observed in patients withbenign breast diseases. IL-18 was found to beoverexpressed in tumor tissues of pancreatic carcinomapatients28 and ovarian cancer patients.12Contrarily, Chia
et al.53 observed significantly higher incidence of IL-18expression in hepatocytes of apparently normalsurrounding tissue compared with the tumor tissue inhepatocellular carcinoma and Cui et al.54 showed thatexpression of IL-18 increased in colorectal adenomatissues than in coloreactal cancer tissues. Further, Chia
et al.53 and Srabovic et al.52 did not find any associationbetween IL-18 expression and histopathological factorsin hepatocellular cancer and breast cancer patients,respectively, which is similar to our findings. Further,some researchers have observed that expression ofIL-18 was significantly associated with poor prognosis.6However, the results of present study showed that IL-18had no significant prognostic role in PTC patients. Thismay be because the overall incidence of disease relapseand mortality is very less in PTC patients and so it mightbe necessary to follow them for a longer period of time.Similar to current findings, IL-18 was not found to beassociated with prognosis in patients with gastriccancer,11, 55 esophageal carcinoma,25 and lung cancer.22In their study, Liu et al.56 have reported that IL-18played an important role in the inhibition of tonguesquamous cell carcinoma and may be furtherinvestigated as a new therapeutic target against thiscancer. Based on preclinical studies, many clinical trialsof IL-18 are been conducted. Collectively, they show thatIL-18 has low toxicity but has limited therapeutic effectsas a single agent. However, IL-18 may be incorporated asan immune enhancing molecule in combinationaltherapies with other agents (e.g. mAb, cytotoxic drugs,or vaccines). Although recent literature has uncovered a
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complex and divergent role of the IL–18 / IL-18R /IL-18BP system in different neoplastic conditions, morestudies on the biologic role of cancer - related IL-18 arecrucial.57 Apart from this, very recently, Ma et al.58 havesuggested that although much needs to be done toexpound the conflicting role of IL18, inclusion of IL18 inimmune checkpoint blockade therapy may extend theevolving treatment regime of cancer.
5. ConclusionOverall from current results it can be implicated that,although high serum IL-18 is not useful as a significantprognosticator, it may be useful as a differentiatingfactor in thyroid tumorigenesis and the increase inserum IL-18 levels may be induced in response to thetumor and is associated with host defence mechanismagainst the tumor cells. Thus, integrating IL-18 into thepresent treatment strategy may have impact inenhancing the immune system to conquer the disease.
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